Cargando…
Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days
A 77-year-old Japanese man presented to our hospital with a 1-month history of low back pain and was diagnosed as having stage IV EGFR mutation-positive lung adenocarcinoma. After treatment with EGFR tyrosine kinase inhibitor and cytotoxic chemotherapy, nivolumab was started as fourth-line therapy....
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470530/ https://www.ncbi.nlm.nih.gov/pubmed/28649487 http://dx.doi.org/10.1016/j.rmcr.2017.05.015 |
_version_ | 1783243782757548032 |
---|---|
author | Iijima, Yuki Hirotsu, Yosuke Amemiya, Kenji Higashi, Seishi Miyashita, Yoshihiro Omata, Masao |
author_facet | Iijima, Yuki Hirotsu, Yosuke Amemiya, Kenji Higashi, Seishi Miyashita, Yoshihiro Omata, Masao |
author_sort | Iijima, Yuki |
collection | PubMed |
description | A 77-year-old Japanese man presented to our hospital with a 1-month history of low back pain and was diagnosed as having stage IV EGFR mutation-positive lung adenocarcinoma. After treatment with EGFR tyrosine kinase inhibitor and cytotoxic chemotherapy, nivolumab was started as fourth-line therapy. Remarkable regression of the primary tumor was observed, suggesting high anti-tumor activity of nivolumab. We retrospectively investigated the change in circulating tumor DNA (ctDNA) variant allele fractions in serial plasma samples before and after the nivolumab therapy. Targeted sequencing analysis showed tumor-derived TP53(R249S) and EGFR(L858R) mutations detectable in plasma, and the timing of decrease was only 5 days, much earlier than the appearance of radiological changes. Overall, these results suggest that ctDNA might reflect tumor burden and might be a surrogate marker of the therapeutic efficacy of immune checkpoint therapy. |
format | Online Article Text |
id | pubmed-5470530 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-54705302017-06-23 Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days Iijima, Yuki Hirotsu, Yosuke Amemiya, Kenji Higashi, Seishi Miyashita, Yoshihiro Omata, Masao Respir Med Case Rep Case Report A 77-year-old Japanese man presented to our hospital with a 1-month history of low back pain and was diagnosed as having stage IV EGFR mutation-positive lung adenocarcinoma. After treatment with EGFR tyrosine kinase inhibitor and cytotoxic chemotherapy, nivolumab was started as fourth-line therapy. Remarkable regression of the primary tumor was observed, suggesting high anti-tumor activity of nivolumab. We retrospectively investigated the change in circulating tumor DNA (ctDNA) variant allele fractions in serial plasma samples before and after the nivolumab therapy. Targeted sequencing analysis showed tumor-derived TP53(R249S) and EGFR(L858R) mutations detectable in plasma, and the timing of decrease was only 5 days, much earlier than the appearance of radiological changes. Overall, these results suggest that ctDNA might reflect tumor burden and might be a surrogate marker of the therapeutic efficacy of immune checkpoint therapy. Elsevier 2017-06-05 /pmc/articles/PMC5470530/ /pubmed/28649487 http://dx.doi.org/10.1016/j.rmcr.2017.05.015 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Iijima, Yuki Hirotsu, Yosuke Amemiya, Kenji Higashi, Seishi Miyashita, Yoshihiro Omata, Masao Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days |
title | Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days |
title_full | Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days |
title_fullStr | Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days |
title_full_unstemmed | Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days |
title_short | Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days |
title_sort | rapid decrease of circulating tumor dna predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470530/ https://www.ncbi.nlm.nih.gov/pubmed/28649487 http://dx.doi.org/10.1016/j.rmcr.2017.05.015 |
work_keys_str_mv | AT iijimayuki rapiddecreaseofcirculatingtumordnapredictedthetreatmenteffectofnivolumabinalungcancerpatientwithinonly5days AT hirotsuyosuke rapiddecreaseofcirculatingtumordnapredictedthetreatmenteffectofnivolumabinalungcancerpatientwithinonly5days AT amemiyakenji rapiddecreaseofcirculatingtumordnapredictedthetreatmenteffectofnivolumabinalungcancerpatientwithinonly5days AT higashiseishi rapiddecreaseofcirculatingtumordnapredictedthetreatmenteffectofnivolumabinalungcancerpatientwithinonly5days AT miyashitayoshihiro rapiddecreaseofcirculatingtumordnapredictedthetreatmenteffectofnivolumabinalungcancerpatientwithinonly5days AT omatamasao rapiddecreaseofcirculatingtumordnapredictedthetreatmenteffectofnivolumabinalungcancerpatientwithinonly5days |